Open Nav

IngenoVax LLC

  • Tim Erickson, IngenoVax

Generate investment conversations to finance lead candidate through IND and Phase I

  • Date:Wednesday, October 17
  • Time:3:15 PM - 3:30 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:IngenoVax has developed and patented Microbial Mimetics (MM), a novel, bio-inspired vaccine platform composed of “fully-synthetic viruses.” MM uniquely addresses the major mechanistic flaws of previously trialed therapeutic cancer vaccines, and of those currently in trials, by supplying the diverse array of immunological signals required to elicit a robust cellular immune response. Founded upon MM, IngenoVax’s mission is to trial and commercialize best-in-class vaccines for solid tumor cancers and infectious diseases. The company’s lead candidate (MM-001) is an off-the-shelf precision immunotherapy targeting a currently undruggable target in a well-defined patient population comprised of pancreatic and colorectal cancers on a tumor-mutation/HLA basis. The MM platform is also readily-loadable with other common- or patient-specific-antigens to treat an even broader range of solid tumor cancers, including melanoma, lung, medullary thyroid, prostate, and breast, among others.
  • Company
  • Company HQ City:Broomfield
  • Company HQ Country:United States
  • Company HQ State:Colorado                   
  • CEO/Top Company Official:Tim Erickson, PhD
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Microbial Mimetics Cancer Vaccine Platform
  • Development Phase of Primary Product:Pre-Clinical
  • Previous and Current Investors:Angel
  • Total Amount Raised to Date, In All Rounds:< $500,000
Tim Erickson